Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Washington University in St. Louis, Mayo Clinic, Mayo Clinic Hospital, University of Colorado Cancer Center, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Johns Hopkins University, Stanford Medicine, Stanford University, University of Washington, Seagen (United States), Duke Medical Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4206727266